Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis

Cited by (292)

Items 101–200 of 292

1. Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers
   Gerald Bastian Schulz, Severin Rodler, Bernadett Emma Szabados, Annabel Graser, Alexander Büchner, Christian Georg Stief, Jozefina Casuscelli · 2020 · Journal of Geriatric Oncology
2. dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
   Liran Holtzman, Mor Tal Moskovitz, Damien Urban, Hovav Nechushtan, Shoshana Keren, Daniel Jack Reinhorn, Mira Wollner, Sameh Daher, Yakir Rottenberg, Yulia Rovitzky et al. · 2021 · Clinical Lung Cancer
3. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
   Monica Pierro, Capucine Baldini, Édouard Auclin, Hélène Vincent, Andreea Varga, Patricia Martin Romano, Perrine Vuagnat, Benjamin Besse, David Planchard, Antoine Hollebecque et al. · 2022 · Cancers
4. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
   Sebastiano Buti, Pierre I. Karakiewicz, Melissa Bersanelli, Umberto Capitanio A, Zhe Tian, Alessio Cortellini, Satoru Taguchi, Alberto Briganti, Francesco Montorsi, Francesco Leonardi et al. · 2019 · Scientific Reports
5. Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
   Michele Montrone, Gerardo Rosati, Vito Longo, Annamaria Catino, Raffaella Massafra, Annalisa Nardone, Francesco Pesola, Elisabetta Sara Montagna, Ilaria Marech, Pamela Pizzutilo et al. · 2023 · Journal of Clinical Medicine
6. Gut microbiota and immunosenescence in cancer
   Yaozheng Xu, Chuan He, Ying Xi, Yue Zhang, Yibo Bai · 2024 · Seminars in Cancer Biology
7. Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
   Vaianu Leroy, Émilie Gerard, Caroline Dutriaux, Sorilla Prey, Aurelia Gey, C. Mertens, Marie Beylot-Barry, Anne Pham‐Ledard · 2019 · Cancer Immunology Immunotherapy
8. Highlights on immune checkpoint inhibitors in non–small cell lung cancer
   Meng Shen, Xiubao Ren · 2017 · Tumor Biology
9. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck
   Khalil Saleh, Anne Auperin, Nicolas Martin, Édith Borcoman, Nouritza Torossian, Mariana Iacob, François‐Régis Ferrand, Nadine Khalife, Neus Basté, Joël Guigay et al. · 2021 · European Journal of Cancer
10. Baseline risk factors associated with immune related adverse events and atezolizumab
    Katrin Madjar, Rajat Mohindra, Gonzalo Durán-Pacheco, Rashad Rasul, Laurent Essioux, Vidya Maiya, G. Scott Chandler · 2023 · Frontiers in Oncology
11. Treatment of head and neck cancer in the elderly
    Stefan Hartmann, Jennifer Rubin Grandis · 2016 · Expert Opinion on Pharmacotherapy
12. Immunotherapy for older patients with melanoma: From darkness to light?
    Donatella Iacono, Maria Grazia Vitale, Debora Basile, Giacomo Pelizzari, Marika Cinausero, Elena Poletto, Gaetano Pascoletti, Alessandro Marco Minisini · 2020 · Pigment Cell & Melanoma Research
13. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review
    Charles Naltet, Benjamin Besse · 2021 · Translational Lung Cancer Research
14. NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice
    Junlei Hou, Shuanglong Xie, Jianbao Gao, Tao Jiang, Enjian Zhu, Xuezhi Yang, Zheng Jin, Haixia Long, Anmei Zhang, Fei Yang et al. · 2024 · Experimental Hematology and Oncology
15. Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
    B. Fox, María de Toro Carmena, Rosa Maria Alvarez, Antonio Calles, C. López López, Sara Ramírez, José Ángel Arranz, Miguel Martín, Iván Márquez‐Rodas · 2019 · Clinical & Translational Oncology
16. Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non–Small-Cell Lung Cancer Patients Treated With the Anti–PD-L1 Antibody
    Sheng Jin, Huadi Wang, Xiao Liu, Yunyun Deng, Yingying Yu, Pengfei Xu, Jiawei Shou, Hong Pan, Hongsen Li, Xiaoyun Zhou et al. · 2021 · Frontiers in Molecular Biosciences
17. Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
    Johannes Kleemann, Manuel Jäger, Eva Maria Valesky, Stefan Kippenberger, Roland Kaufmann, Markus Meißner · 2021 · Cancer Management and Research
18. Immunotherapy in Older Adults: A Checkpoint to Palliation?
    Rawad Elias, Oreofe Olukemi Odejide · 2019 · American Society of Clinical Oncology Educational Book
19. Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
    Bożena Cybulska-Stopa, Iwona A. Lugowska, Paulina Jagodzińska-Mucha, Hanna Koseła-Paterczyk, Katarzyna Kozak, Anna Klimczak, Tomasz Świtaj, Marek Ziobro, Agnieszka Roman, Marcin Rajczykowski et al. · 2019 · Advances in Dermatology and Allergology
20. Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features
    Gengwei Huo, Wenjie Liu, Peng Chen · 2022 · Frontiers in Immunology
21. Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction
    Vaia Florou, Sonam Puri, Ignacio Garrido‐Laguna, Breelyn Ann Wilky · 2021 · Annals of Translational Medicine
22. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
    Yuki Nemoto, Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2021 · International Urology and Nephrology
23. Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
    Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira · 2022 · World Journal of Surgical Oncology
24. Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results
    Dimitrios C. Ziogas, Charalampos Theocharopoulos, Katerina Aravantinou-Fatorou, Aristeidis E. Boukouris, Dimitra T. Stefanou, Amalia N. Anastasopoulou, Peter Lialios, George Lyrarakis, Helen J Gogas · 2025 · Critical Reviews in Oncology/Hematology
25. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody
    Shijin Yuan, Yan Xia, Lihong Shen, Liuqing Ye, Lisha Li, Lifen Chen, Xinyou Xie, Haizhou Lou, Jun Zhang · 2020 · Cancer Immunology Immunotherapy
26. Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors
    Gray Jodon, Stacy M. Fischer, Elizabeth Riley Kessler · 2018 · Drugs & Aging
27. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis
    Shuyue Zheng, Huijuan Cui, Hua Duan, Yang Peng, QiSha Li, Chenyao Sun, Junchi Zhang, Wen Shen, X. Zhang, K. Tan et al. · 2019 · Clinical & Translational Oncology
28. Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status
    Mohit Butaney, Raj Satkunasivam, Hanan Goldberg, Stephen J. Freedland, Sandip Pravin Patel, Omid Hamid, Sumanta Kumar Pal, Zachary William Abraham Klaassen, Christopher J. D. Wallis · 2019 · American Journal of Clinical Oncology
29. Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy
    Jnaneshwari Pradeep, Thin Thin Win, Saint Nway Aye, Chandrashekhar T Sreeramareddy · 2022 · Journal of Cancer
30. Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors
    Ahmad A. Alharbi, Attiah Khobrani, Afnan Noor, Waad Alghamdi, Abdulmalik S. Alotaibi, Mohammed A. Alnuhait, Abdul Haseeb · 2022 · International Journal of Environmental Research and Public Health
31. Considerations and Approaches for Cancer Immunotherapy in the Aging Host
    Carlos Oscar Ontiveros, Clare E. Murray, Grace E. Crossland, Tyler Jay Curiel · 2023 · Cancer Immunology Research
32. Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
    Khalil Choucair, Abdul Rafeh Naqash, Caroline A. Nebhan, Ryan David Nipp, Douglas Buckner Johnson, Anwaar Saeed · 2022 · The Oncologist
33. The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis
    Jiaxin Yin, Yuxiao Song, Yang Fu, Jun Wang, Jiazhuo Tang, Zhimin Zhang, Qibin Song, Bicheng Zhang · 2023 · Aging
34. Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis
    Zexi Xu, Jia Feng, Yiming Weng, Yao Jin, Min Peng · 2021 · Journal of Oncology
35. Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
    Yunzhen Wang, Sha Huang, Xiangwei Feng, Wangjue Xu, Raojun Luo, Ziyi Zhu, Qingxin Zeng, Zhengfu He · 2023 · Frontiers in Oncology
36. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma
    Bin Zhao, Hong Zhao, Jiaxin Zhao · 2018 · International Journal of Cancer
37. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma
    Hiroyuki Ohashi, Sora Takeuchi, Tomomitsu Miyagaki, Takafumi Kadono · 2020 · Drug Discoveries & Therapeutics
38. Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years
    Fausto Petrelli, Alessandro Inno, Antonio Ghidini, Stefania Gori, Melissa Bersanelli · 2020 · Cancer Immunology Immunotherapy
39. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry
    Anouk Jochems, Esther Bastiaannet, Maureen J.B. Aarts, Alexander C. J. van Akkooi, Franchette W.P.J. van den Berkmortel, Marye J. Boers‐Sonderen, Alfons J.M. van den Eertwegh, Nienke Aafke de Glas, Jan Willem B. de Groot, John B.A.G. Haanen et al. · 2021 · Journal of Geriatric Oncology
40. Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper
    Deniz Can Güven, Bertha Alejandra Martínez-Cannon, Giuseppe Dario Testa, Janine Capobiango Martins, Rogelio Velasco, Tania Kalsi, Fábio Gomes · 2024 · Journal of Geriatric Oncology
41. PD1 blockade improves survival and CD8+ cytotoxic capacity, without increasing inflammation, during normal microbial experience in old mice
    Korbyn J.V. Dahlquist, Matthew A. Huggins, Matthew J. Yousefzadeh, Carolina Soto-Palma, Stephanie H. Cholensky, Mark J. Pierson, Declan M. Smith, Sara E. Hamilton, Christina D. Camell · 2024 · Nature Aging
42. Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions
    Huatao Zhou, Zilong Zheng, Chengming Fan, Zijing Zhou · 2025 · Seminars in Cancer Biology
43. Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
    Taichi Matsubara, Takashi Seto, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Tatsuro Okamoto · 2021 · OncoTargets and Therapy
44. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy
    Beibei Guo, Yong Zang · 2022 · Statistical Methods in Medical Research
45. Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors
    Frank R. Rojas, Edwin Roger Parra, Ignacio Ivan Wistuba, Cara Haymaker, Luisa M. Solis Soto · 2022 · Cancers
46. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab
    Francesco Pantano, Marco Russano, Alfredo Berruti, Giovanni Mansueto, Maria Rita Migliorino, Vincenzo Adamo, Giuseppe Aprile, Alain Jonathan Gelibter, Corrado Ficorella, Alfredo Falcone et al. · 2020 · Expert Opinion on Biological Therapy
47. Pembrolizumab use for the treatment of advanced melanoma
    Pol M. Specenier · 2017 · Expert Opinion on Biological Therapy
48. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching
    Naotaka Nishiyama, Takashi Kobayashi, Shintaro Narita, Yu Hidaka, Katsuhiro Ito, Satoru Maruyama, Shoichiro Mukai, Masakazu Tsutsumi, Jun Miki, Tomoya Okuno et al. · 2021 · Journal of Geriatric Oncology
49. Efficacy of Immune Checkpoint Inhibitors in Cancer Patients of Different Ages: A Meta-Analysis
    Jing Li, Jian Hong Gu · 2019 · Future Oncology
50. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer
    Mehmet Altan, Eric Kumar Singhi, Michelle Arielle Worst, Brett W. Carter, Cheuk Hong Leung, J. Jack Lee, Carolyn Jean Presley, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong et al. · 2022 · Clinical Lung Cancer
51. Unique characteristics of the tumor immune microenvironment in young patients with metastatic colorectal cancer
    Brian D. Griffith, Jenny Lazarus, Jake J. McGue, Santhoshi Krishnan, Michael Ian D'Angelica, Jinru Shia, Irina Y. Dobrosotskaya, Jiaqi Shi, Jacob Edwards, Arvind U.K. Rao et al. · 2023 · Frontiers in Immunology
52. Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
    Dengyong Zhang, Yan Zhu, Zhengchao Shen, Shuoshuo Ma, Sihua Liu, Zheng Lu · 2025 · Seminars in Cancer Biology
53. Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis
    Qian Qin, Tomi Wei Jun, Bo Wang, Vaibhav G. Patel, George Slade Mellgard, Xiaobo Zhong, Mahalya Gogerly-Moragoda, Anish B. Parikh, Amanda Leiter, Emily J. Gallagher et al. · 2022 · Discover Oncology
54. Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes
    Kazuyuki Numakura, Mizuki Kobayashi, Shingo Hatakeyama, Sei Naito, Yohei Horikawa, Toshikazu D. Tanaka, Sachiko Kamada, Yumina Muto, Ryohei Yamamoto, Atsushi Koizumi et al. · 2020 · International Journal of Clinical Oncology
55. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD‐1/PD‐L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta‐Analysis
    Yuhan Wei, Yongfu Li, Qi Du, Xinyi Peng, Jiangtao Jin, Hong Yan Guo, Yongyan Li, Qin Li · 2020 · Journal of Immunology Research
56. Challenges in the combination of radiotherapy and immunotherapy for breast cancer
    Rui Zhang, S. Clark, Beibei Guo, Tianyi Zhang, Duane P. Jeansonne, Samithamby Jeyaseelan, Joseph Francis, Weishan Huang · 2023 · Expert Review of Anticancer Therapy
57. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
    Meng Li, Denis Kaili, Lei Shi · 2022 · World Journal of Gastrointestinal Oncology
58. Investigating the Quality of Life for Cancer Patients and Estimating the Cost of Immunotherapy in Selected Cases
    Georgios Fragkiadakis, Maria Spiliotopoulou · 2022 · Cureus
59. Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
    Jun Wang, Bicheng Zhang, Ling Peng, Xiufeng Liu, Jianguo Sun, Chunxia Su, Huijuan Wang, Zheng Zhao, Lu Si, Jianchun Duan et al. · 2023 · Therapeutic Advances in Medical Oncology
60. Checkpoint Inhibitors, Palliative Care, or Hospice
    Mellar P. Davis, Rajiv Prasanna Panikkar · 2018 · Current Oncology Reports
61. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
    Wenjie Liu, Gengwei Huo, Peng Chen · 2022 · Frontiers in Immunology
62. The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer
    José María Mazarico Gallego, Mercedes Herrera Juárez, Luis G Paz-Ares · 2020 · Expert Opinion on Drug Safety
63. Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
    Khalil Choucair, Caroline A. Nebhan, Alessio Cortellini, Stijn Hentzen, Yinghong Wang, Cynthia Liu, Raffaele Giusti, Marco Filetti, Paolo A. Ascierto, Vito Vanella et al. · 2023 · Cancers
64. From clinical trials to real-world practice: Immune checkpoint inhibitors in older adults
    Kah Poh Loh, Melisa L. Wong, Ronald John Maggiore · 2019 · Journal of Geriatric Oncology
65. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients’ Age: A Systematic Review and Meta-Analysis
    Chiara Ciccarese, Roberto Iacovelli, Emilio Bria, Antonella Palazzo, Brigida Anna Maiorano, Claudia Mosillo, Carmine Carbone, Geny Piro, Giampaolo Tortora · 2020 · Journal of Immunotherapy
66. Immune Checkpoint Inhibitors in the Aged
    James M. Isaacs, Scott Joseph Antonia, Jeffrey Melson Clarke · 2021 · Current Oncology Reports
67. Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges
    Chuling Li, Yong Song · 2021 · Chinese Medical Journal
68. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non–small-cell Lung Cancer
    Tao Jiang, Hongcheng Liu, Meng Qiao, Xuefei Li, Chao Zhao, Chunxia Su, Shengxiang Ren, Caicun Zhou · 2017 · Clinical Lung Cancer
69. A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma
    Cristian Lolli, Amelia Altavilla, Vincenza Conteduca, Alberto Farolfi, Chiara Casadei, Giuseppe Schepisi, Giuseppe Luigi Banna, Ugo De Giorgi · 2020 · Critical Reviews in Oncology/Hematology
70. Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer
    Yacki Hayashi‐Tanner, Peter James Polewski, Mamatha Gaddam, Nancy R. Fisher, Attila J. Kovacs, David E. Marinier · 2022 · Journal of Geriatric Oncology
71. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG
    Takamitsu Inoue, Makito Miyake, Nobutaka Nishimura, Mizuki Onozawa, Soki Kashima, Kazuyuki Numakura, Shintaro Narita, Kota Iida, Motohide Uemura, Yuto Matsushita et al. · 2022 · Urology
72. Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
    Takeshi Okamoto, Eriko Nakano, Teruo Yamauchi · 2021 · Journal of Medical Case Reports
73. Immunotherapy in elderly head and neck cancer patients: a systematic review and meta-analysis
    Viola Salvestrini, Saverio Caini, Melissa Scricciolo, Michael Saerens, Heleen Bollen, Pierluigi Bonomo, Francesca Caparrotti, Luigi Lorini, Marc Oliva, Maria Urbanowicz-Nijaki et al. · 2024 · Frontiers in Oncology
74. T-cell senescence: Unlocking the tumor immune “Dark Box” - A multidimensional analysis from mechanism to tumor immunotherapeutic intervention
    Jia Cheng, Jian Zheng, Chen Ma, Yongzhang Li, Hua Hao · 2025 · Seminars in Cancer Biology
75. Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data
    Marko B. Lens, Jacob Schachter · 2025 · Cancers
76. Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma
    Ashley V. Howell, Mulugeta Gebregziabher, BRUCE H. THIERS, Chrystal Mary Paulos, John M. Wrangle, Kelly J. Hunt, Kristin Wallace · 2020 · Journal of Geriatric Oncology
77. Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis
    Gengwei Huo, Wenjie Liu, Sipei Zhang, Peng Chen · 2023 · Immunotherapy
78. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection
    S. Klein, Dario Ghersi, Michael Peter Manns, Immo Prinz, Markus Cornberg, Anke R.M. Kraft · 2020 · Journal of Virology
79. The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy
    Joanne K. Gardner, Connie Jackaman, Cyril D S Mamotte, Delia Jane Nelson · 2018 · Frontiers in Medicine
80. Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper
    Nicolò Matteo Luca Battisti, Gabor Istvan Liposits, Nienke A. de Glas, Fábio Gomes, Capucine Baldini, Supriya Gupta Mohile · 2020 · Current Oncology Reports
81. Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
    Bożena Cybulska-Stopa, Marcin Ziętek, Grażyna Kamińska‐Winciorek, Anna Malgorzata Czarnecka, Karolina Piejko, Łukasz Galus, Barbara Ziółkowska, Stanisław Kieszko, Natasza Kempa-Kamińska, Jacek Calik et al. · 2020 · Melanoma Research
82. Anal cancer in older adults: A Young International Society of Geriatric Oncology review paper
    Bertha Alejandra Martínez-Cannon, Ana Cristina Torres-Pérez, Jacobo Hincapie-Echeverri, Mukul Roy, Joana Catarina Lima Marinho, Gabriela Alejandra Buerba, Baran Akagündüz, Daneng Li, Enrique Soto‐Pérez‐de‐Celis · 2022 · Journal of Geriatric Oncology
83. [Retracted] GNAI2 Is a Risk Factor for Gastric Cancer: Study of Tumor Microenvironment (TME) and Establishment of Immune Risk Score (IRS)
    Han Yu, Sha Liu, Zuguang Wu, Fenfei Gao · 2022 · Oxidative Medicine and Cellular Longevity · Retracted
84. Global research trends of immunosenescence: A bibliometric study
    Hongbo Chen, Yiwei Luo, Xiaohong Zhang, Ruzhen Luo, Yuhong Bian, Yunlong Hou, Yanhui Liu · 2023 · Heliyon
85. Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma
    Héloïse Barailler, Guillemette Salomon, Caroline Dutriaux, Sorilla Prey, Émilie Gerard, L. Dousset, C. Mertens, Marie Beylot-Barry, Nicolás Meyer, Anne Pham‐Ledard · 2020 · Journal of Geriatric Oncology
86. Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents
    C. Terret, Chiara Russo · 2018 · Drugs & Aging
87. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
    Taylor Evart Woo, Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael S. Sander, Benjamin W. Ewanchuk, Winson Y. Cheung, Daniel Y.C. Heng, Tina Cheng · 2023 · Current Oncology
88. Young lung cancer: from diagnosis to survivorship
    Narjust Florez, Lauren Kiel, Rebekah A. Kaufman, Jaclyn LoPiccolo, Biagio Ricciuti, Angela S. Morabito, Olayinka Fakorede, Courtney Mantz, Coral Olazagasti, Nishwant S. Swami et al. · 2025 · Frontiers in Oncology
89. Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development
    Yiyuan Feng, Caiying He, Chang Liu, Bingjie Shao, Dong Wang, Peijie Wu · 2024 · International Journal of Molecular Sciences
90. Immune signatures predicting responses to immunomodulatory antibody therapy
    Graham Pawelec · 2018 · Current Opinion in Immunology
91. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors
    Ashley V. Howell, Mulugeta Gebregziabher, BRUCE H. THIERS, Evan Michael Graboyes, Chrystal Mary Paulos, John M. Wrangle, Kelly J. Hunt, Kristin Wallace · 2022 · Journal of Geriatric Oncology
92. Circular RNAs in cancer immunology: Immune escape, therapeutic resistance, and nanomedicine synergies
    Bo Lv, Lan Li, Man Liu, Suzhao Zou · 2025 · Translational Oncology
93. Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors
    Yuya Hirasawa, Junya Isobe, Masahiro Hosonuma, Toshiaki Tsurui, Yuta Baba, Eiji Funayama, Kohei Tajima, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda et al. · 2025 · Frontiers in Immunology
94. Selected updates in molecular and genomic pathology of esophageal cancer
    Yueping Liu, Lei Zhao, Liyan Xue, Yingyong Hou · 2020 · Annals of the New York Academy of Sciences
95. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
    Nadine J. McCleary, William Scott Harmsen, Ellana K. Haakenstad, James M. Cleary, Jeffrey A. Meyerhardt, John Raymond Zalcberg, Richard Adams, Axel F. Grothey, Alberto Felice Sobrero, Eric Van Cutsem et al. · 2022 · JNCI Cancer Spectrum
96. Checkpoint inhibitors in older patients with advanced non-small cell lung cancer
    Maria Lucia Reale, Gianpiero Diego Romano, Loretta Paolelli, Silvana Leo · 2023 · Critical Reviews in Oncology/Hematology
97. Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM)
    Marion Detroit, Mathis Collier, Nathanaël Beeker, Lise Willems, Justine Decroocq, Bénédicte Deau, Marguerite Vignon, Rudy Birsen, Frederique Moufle, Clément Leclaire et al. · 2023 · Cancers
98. Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies
    Daosong Dong, Yu Xue, Haoran Liu, Jingjing Xu, Jiayan Guo, Wei Guo, Xiang Li, Fei Wang, Dongyong Zhang, Kaiwei Liu et al. · 2025 · Seminars in Cancer Biology
99. Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports
    Rishu Takimoto, Takashi Kamigaki, Takuji Gotoda, Toshimi Takahashi, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Shigenori Goto · 2021 · Journal of Medical Case Reports
100. Immunotherapy for older patients with cancer
     Tatianny P. Araujo Vargas, Abdullah Al-Humiqani, Danilo Giffoni de Mello Morais Mata, Ines B. Menjak · 2023 · Current Opinion in Supportive and Palliative Care